Welcome to our dedicated page for Revvity SEC filings (Ticker: RVTY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Revvity, Inc.'s SEC filings document operating results, governance matters and capital-structure disclosures for a Massachusetts-incorporated life sciences and diagnostics company. Its 8-K reports furnish quarterly and annual financial results, preliminary performance updates, Regulation FD investor presentation materials and other material-event disclosures.
Proxy and annual-meeting filings describe director elections, auditor ratification, advisory executive-compensation votes and shareholder-approved bylaw amendments, including the ability of holders of 25% of the company's stock to call a special meeting. Other current reports identify registered securities, including RVTY common stock and 1.875% notes due 2026 listed on the New York Stock Exchange, as well as officer appointments and related governance changes.
RVTY has a planned insider sale of common stock under Rule 144. The notice covers 12,717 common shares to be sold through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of $1,274,382.22.
The shares relate to a stock option granted on 02/05/2019 and acquired on 02/05/2026, with the purchase price paid in cash. The filing notes that 113,375,621 shares of the issuer’s common stock were outstanding, providing context for the size of the planned sale.
Revvity, Inc. executive Tajinder S. Vohra exercised and sold stock options in a planned transaction. On 02/02/2026, Vohra exercised a nonqualified stock option for 5,756 shares of common stock at $92.09 per share, then sold 5,756 shares at $104.5 per share.
The option, which vested in three equal annual installments beginning on February 5, 2020, was fully exercised, leaving 0 derivative securities. After the sale, Vohra directly owned 10,442 shares of Revvity common stock. The sale was made under a pre-established Rule 10b5-1 trading plan adopted on February 20, 2025. Vohra serves as Senior Vice President, Global Operations.
A holder of RVTY common stock has filed a Rule 144 notice to sell 5,756 shares through Fidelity Brokerage Services LLC on the NYSE around 02/02/2026, with an aggregate market value of 601502.00.
The issuer had 113,375,621 shares of common stock outstanding. The shares to be sold were acquired as a result of stock options granted on 02/05/2019 and exercised for cash on 02/02/2026.
Revvity, Inc. furnished an update on its performance by announcing financial results for the fourth quarter and full fiscal year ended December 28, 2025. The company released these results through a press release dated February 2, 2026, which is provided as Exhibit 99.1 and treated as furnished, not filed, under securities law.
Revvity, Inc. filed a current report describing upcoming financial communications and an investor presentation. The company announced preliminary expectations for certain financial results for its fourth quarter ended December 28, 2025 and said it will release full fourth quarter and full year 2025 financial results on February 2, 2026. These details are contained in a press release furnished as an exhibit.
The filing also notes that President and CEO Dr. Prahlad Singh is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, with the presentation materials furnished as a separate exhibit. Both the press release and the presentation are being furnished rather than filed, which limits their exposure to certain Exchange Act liabilities.
Revvity, Inc. executive Anita Gonzales, Vice President and Chief Accounting Officer, reported a small insider stock transaction. On 12/15/2025, 25 shares of common stock were disposed of at $100.49 per share, coded as an "F" transaction.
According to the footnote, these shares were surrendered to satisfy tax withholding obligations upon vesting of restricted stock units originally granted on 12/15/2023 under her Restricted Stock Unit Agreement. Following this automatic tax-withholding event, she beneficially owns 4,315 shares of Revvity common stock directly.
Revvity, Inc. (RVTY): Schedule 13G/A — Janus Henderson Group plc reported beneficial ownership of 7,627,259 American Depositary Shares, representing 6.6% of the class. The filer reported 0 sole voting and dispositive power and 7,627,259 shared voting and dispositive power. The filing is certified as being made in the ordinary course and not for the purpose of changing or influencing control.
Separately, the filing notes that Janus Henderson Investors US LLC (JHIUS) may be deemed to beneficially own 7,588,607 shares, or 6.5%, with shared voting and dispositive power and no sole powers. The report identifies the reporting person’s type as IA, HC and includes a standing power of attorney for signature authority.
Revvity, Inc. received a Schedule 13G/A (Amendment No. 1) from EdgePoint Investment Group Inc. disclosing a passive stake. EdgePoint reports beneficial ownership of 8,574,280 shares of common stock, representing 7.39% of the class as of the event date.
EdgePoint has sole voting and dispositive power over 5,628,116 shares and shared voting and dispositive power over 2,946,164 shares. The certification states the securities were acquired and are held in the ordinary course and not for the purpose of changing or influencing control.
Revvity, Inc. (RVTY) reported Q3 results with total revenue of $698.9 million, up 2% year over year. Diluted EPS was $0.40 as net income declined to $46.7 million amid higher interest and other expenses. Gross margin fell 266 bps to 53.6% and operating margin also compressed, driven by increased tariffs, unfavorable foreign exchange, and product mix.
By segment, Diagnostics rose 3% to $356.1 million, led by Reproductive Health, while Life Sciences inched up 1% to $342.8 million on stronger Software. Year‑to‑date cash from operations was $407.0 million. The company repurchased 6.75 million shares for $647.9 million year to date, ending the quarter with 114.0 million shares outstanding, and the Board authorized a new $1.0 billion repurchase program on October 23, 2025. The quarterly dividend remained $0.07 per share.
Revvity, Inc. (RVTY) President, Chief Executive Officer and Director Prahlad R. Singh reported a bona fide gift of 9,420 shares of common stock on 10/29/2025.
The shares were transferred to an irrevocable trust for the sole benefit of his children, with his spouse serving as trustee. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest.
Following the transaction as of October 29, 2025, Singh beneficially owned 96,838 shares direct and 46,583 shares indirect through the Singh Family Trust of 2021.